Osiris Therapeutics, Inc. (NASDAQ: OSIR), today provided an update on the status of the development and commercialization agreement with Genzyme, a Sanofi company. On Wednesday, February 8, 2012, Sanofi issued a press release, which included an update on their R&D pipeline, stating that it ... read more

Zalicus Inc. (NASDAQ: ZLCS) a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases and Hydra Biosciences, Inc., a leader in the discovery and development of novel ion channels, today announced that they ... read more

CEL-SCI Corporation (NYSE AMEX: CVM) reports financial results for the fiscal quarter ended December 31, 2011. CEL-SCI reported that net loss available to shareholders for the quarter ended December 31, 2011 was ($4,156,833) versus ($6,250,952) during the same quarter ... read more

Exelixis, Inc. (Nasdaq:EXEL) today announced that it plans to offer, subject to market and other conditions, 10,000,000 shares of its common stock in an underwritten public offering. The company expects to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of ... read more

Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology and obesity, today announced financial results for its fiscal 2012 first quarter ended December 31, 2011. “The first quarter of fiscal 2012 saw transformational change for ... read more

Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, based on clinical data and the opinions of interviewed thought leaders, Regeneron/Bayer HealthCare’s Eylea will earn Decision Resources’ proprietary clinical gold standard status for the treatment of diabetic ... read more

Sorin (MIL:SRN): Consolidated results for the fourth quarter of 2011: Revenues of €197.9 million, a 0.8%1 increase (+1.2% as reported) over the fourth quarter of 2010; ... read more

Puma Biotechnology, Inc., a development stage biopharmaceutical company, announced that Alan H. Auerbach, Chief Executive Officer, President and Founder of Puma, will present an overview of the Company at 3:30 p.m. EST, Thursday, February 16, at the Leerink Swann 2012 Global Healthcare Conference. The conference will ... read more

Courtagen Life Sciences, Inc. (“Courtagen”), a privately held life sciences company that provides innovative proteomic and genomic products and services to the life sciences industry, today announced that it has entered into a strategic collaboration with Tetracore, Inc. (“Tetracore”) to develop a next generation biothreat assay ... read more

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that its scientists have discovered a novel method for monitoring RNAi activity in blood samples, representing a potential major advance for future development of RNAi therapeutics, other therapeutic ... read more

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), announced today that the independent Data Monitoring Committee (DMC) has completed the eighth unblinded review of the LibiGel Phase III cardiovascular and breast cancer safety study, which has completed enrollment of subjects. The independent DMC has recommended that the LibiGel safety ... read more

PaxVax Corporation, developer of innovative and socially responsible oral vaccines against infectious diseases, announced the expansion of its executive management team with the appointments of Nima Farzan as Executive Vice President and Chief Operating Officer, Thomas P. Monath, M.D. as Chief Technology Officer, and Jonathan F. ... read more

ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular” or the “Company”) (OTCBB: IMUC), a biotechnology company focused on the development of novel immune-based cancer therapies, announced today that its president and CEO, Manish Singh Ph.D., will be presenting at the upcoming 14th annual BIO CEO & Investor Conference at the Waldorf Astoria in ... read more

Galectin Therapeutics, Inc. (OTC: GALT), the leading developer of therapeutics that target galectin receptors to treat cancer and fibrosis, today announced that Dr. Peter G. Traber, Chief Executive Officer, President and Chief Medical Officer, is scheduled to present a corporate update at the BIO CEO & ... read more

Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that it has received a Paragraph IV Notice Letter from Hospira, Inc. advising of the filing of an Abbreviated New Drug Application (ANDA) for a generic version of CUBICIN® (daptomycin for injection). ... read more

Date: ... read more

Almac is pleased to announce the doubling of analytical capacity at its 240,000 sq. ft. North American Headquarters. The facility - built on a 40 acre site in Souderton, north of Philadelphia (PA) - and occupied since 2010, delivers full-service, integrated clinical packaging, drug ... read more

Regulatory News: EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX: EPCT) announced today that it has entered into a definitive agreement with a single life science focused institutional investor for the purchase of 2,000 shares of its Series A ... read more

Covington & Burling is adding a highly regarded corporate team to its Beijing and Silicon Valley offices, bolstering Covington’s global transactional capabilities in the technology and life sciences sectors. The firm is pleased to announce that Michelle Edwards, Eva Wang and ... read more

Date: ... read more